Compare Amgen, Inc. (AMGN) vs Invesco DB Commodity Index Tracking Fund (DBC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Invesco DB Commodity Index Tracking Fund — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Invesco DB Commodity Index Tracking Fund trades at $27.24. The key difference: Amgen, Inc. pays a 2.77% dividend while Invesco DB Commodity Index Tracking Fund pays none, and Amgen, Inc. is trading nearer its 52-week high, Invesco DB Commodity Index Tracking Fund nearer its low. Which is the better fit depends on your goals.
| AMGN | DBC | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $388.16 | $31.69 |
52-Week Low | $271.18 | $21.62 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
DBC trades at $27.52, down slightly by 0.22% today, with technical indicators showing a bullish trend supported by moving averages. The commodity ETF recently hit a 52-week high in April 2026, driven by oil supply shocks and safe-haven demand. Recent news highlights commodities as effective inflation hedges, with DBC gaining over 32% in the past year.
The outlook remains positive given strong momentum and institutional interest in commodities for portfolio diversification. Key risks include geopolitical tensions affecting oil supplies and potential market volatility from inflation dynamics. Analyst sentiment is constructive, with DBC positioned to benefit from ongoing commodity strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →
